Isabelle Fournel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Isabelle Fournel has a total of 206 co-authors. Here are the top co-authors by number of shared publications:
- Jean-Pierre Quenot
Department of Intensive Care, Burgundy University Hospital, Dijon, France
8 shared publications - Marie Labruyère
Service de Médecine Intensive-Réanimation, CHU Dijon-Bourgogne, Dijon Cedex, France
4 shared publications Abderrahmane Bourredjem
CHU Dijon Bourgogne, Centre d’Investigation Clinique, module épidémiologie clinique, INSERM, CIC 1432, Université Bourgogne Europe, Dijon, France
3 shared publications- Jean-Philippe Rigaud
Service de Médecine Intensive Réanimation, CH de Dieppe, Dieppe, France
3 shared publications - Julio Badie
Service de Réanimation, Hôpital Nord Franche-Comté, Trévenans, France
3 shared publications - Marine Jacquier
Service de Médecine Intensive-Réanimation, CHU Dijon-Bourgogne, Dijon Cedex, France
3 shared publications
Latest Publications
- Open Access
A normative torque-profile approach for quantifying elbow and wrist flexor hyper-resistance after stroke: a proof-of-principle study
Background: Post-stroke spasticity is commonly assessed using the Modified Ashworth Scale (MAS), despite its limited objectivity and variable reliability. This study introduces Score E , a novel isokinetic dynamometry-derived metric designed to quantify elbow and wrist flexor hyper-resistance by comparing patients’ torque-angle profiles with a healthy reference corridor. Methods: Thirty-five post-stroke patients and twenty-one healthy controls were included. Elbow and wrist hyper-resistance was assessed using the MAS and an isokinetic dynamometer in two testing conditions: seated on the dynamometer chair (ergo chair) and seated in the patient’s wheelchair. Two dynamometer-derived metrics were analyzed: Score E and peak torque (Peakτ). Feasibility, inter-rater and test-retest reliability, and associations with MAS grades were assessed. Exploratory PRE-POST changes following a 10-min local vibration session were also described. Results: Score E showed good to excellent inter-rater and test-retest reliability across joints and testing conditions. Inter-rater ICCs ranged from 0.81 to 0.89, and test-retest ICCs from 0.76 to 0.93. Peakτ showed moderate to good reliability. In contrast, MAS agreement was lower and more variable. Score E showed moderate associations with MAS grades, particularly at the elbow, with weaker and less consistent associations at the wrist. MAS assessment was faster, but all assessments were well tolerated, with median pain ratings of 0/10 in all testing conditions. PRE-POST vibration changes were small and heterogeneous, preventing formal assessment of responsiveness. Conclusion: Score E provides a reliable, objective, and visually interpretable quantification of post-stroke elbow and wrist flexor hyper-resistance. By comparing the full torque-angle profile with normative data, this approach preserves information on both the magnitude and angular span of abnormal resistance, supporting its potential for targeted longitudinal monitoring.
Open AccessA normative torque-profile approach for quantifying elbow and wrist flexor hyper-resistance after stroke: a proof-of-principle study
Background: Post-stroke spasticity is commonly assessed using the Modified Ashworth Scale (MAS), despite its limited objectivity and variable reliability. This study introduces Score E , a novel isokinetic dynamometry-derived metric designed to quantify elbow and wrist flexor hyper-resistance by comparing patients’ torque-angle profiles with a healthy reference corridor. Methods: Thirty-five post-stroke patients and twenty-one healthy controls were included. Elbow and wrist hyper-resistance was assessed using the MAS and an isokinetic dynamometer in two testing conditions: seated on the dynamometer chair (ergo chair) and seated in the patient’s wheelchair. Two dynamometer-derived metrics were analyzed: Score E and peak torque (Peakτ). Feasibility, inter-rater and test-retest reliability, and associations with MAS grades were assessed. Exploratory PRE-POST changes following a 10-min local vibration session were also described. Results: Score E showed good to excellent inter-rater and test-retest reliability across joints and testing conditions. Inter-rater ICCs ranged from 0.81 to 0.89, and test-retest ICCs from 0.76 to 0.93. Peakτ showed moderate to good reliability. In contrast, MAS agreement was lower and more variable. Score E showed moderate associations with MAS grades, particularly at the elbow, with weaker and less consistent associations at the wrist. MAS assessment was faster, but all assessments were well tolerated, with median pain ratings of 0/10 in all testing conditions. PRE-POST vibration changes were small and heterogeneous, preventing formal assessment of responsiveness. Conclusion: Score E provides a reliable, objective, and visually interpretable quantification of post-stroke elbow and wrist flexor hyper-resistance. By comparing the full torque-angle profile with normative data, this approach preserves information on both the magnitude and angular span of abnormal resistance, supporting its potential for targeted longitudinal monitoring.
- Open Access
- 14 July 2026
- Published by MDPI AG in Healthcare
- Vol. 14 (14) , 2105
Impact of Legal Protection on Life-Support Interventions and 3-Month Mortality in the Intensive Care Unit: The Vulne-Rea Study
Background/Objectives: Adults under legal protection experience management delays and prolonged hospitalization. This study investigated whether ICU outcomes differ between patients with versus without legal protection. Methods: This retrospective, single-center study evaluated patients admitted to a French ICU (July 2015–July 2023). Protected patients were compared to autonomous controls matched 1:3 by age and admission year. Results: Of the 1051 patients included, 266 (25.3%) were under legal protection. The protected group had a higher proportion of women (43.2% vs. 35.7%, p = 0.025), received renal replacement therapy less frequently (8.6% vs. 15.4%, p = 0.007), and required non-invasive ventilation more frequently (25.2% vs. 17.2%, p = 0.004) than controls. Three-month mortality was 38.7% in controls versus 33.1% in protected patients, showing no significant difference after multivariable adjustment for 6 prespecified clinical variables (aOR 0.816, 95% CI 0.564 to 1.180). In the adjusted model, higher SAPS II scores and vasopressor use were significantly associated with increased 3-month mortality, whereas non-invasive ventilation and non-respiratory admission indications (sepsis, renal failure, trauma) were associated with decreased mortality. Conclusions: No significant association was observed between the presence of a legal protection measure prior to ICU admission and 3-month patient mortality. However, these results must be interpreted with caution due to a potential lack of statistical power. Additionally, legally protected patients were observed to receive renal replacement therapy less frequently, whereas non-invasive ventilation was utilized more frequently. Within this context, further research is required to evaluate the impact of legal protection status on the formal collegial deliberations that lead to decisions regarding the limitation of life-sustaining treatments.
- 14 July 2026
- Published by MDPI AG in Healthcare
- Vol. 14 (14) , 2105
Open AccessImpact of Legal Protection on Life-Support Interventions and 3-Month Mortality in the Intensive Care Unit: The Vulne-Rea Study
Background/Objectives: Adults under legal protection experience management delays and prolonged hospitalization. This study investigated whether ICU outcomes differ between patients with versus without legal protection. Methods: This retrospective, single-center study evaluated patients admitted to a French ICU (July 2015–July 2023). Protected patients were compared to autonomous controls matched 1:3 by age and admission year. Results: Of the 1051 patients included, 266 (25.3%) were under legal protection. The protected group had a higher proportion of women (43.2% vs. 35.7%, p = 0.025), received renal replacement therapy less frequently (8.6% vs. 15.4%, p = 0.007), and required non-invasive ventilation more frequently (25.2% vs. 17.2%, p = 0.004) than controls. Three-month mortality was 38.7% in controls versus 33.1% in protected patients, showing no significant difference after multivariable adjustment for 6 prespecified clinical variables (aOR 0.816, 95% CI 0.564 to 1.180). In the adjusted model, higher SAPS II scores and vasopressor use were significantly associated with increased 3-month mortality, whereas non-invasive ventilation and non-respiratory admission indications (sepsis, renal failure, trauma) were associated with decreased mortality. Conclusions: No significant association was observed between the presence of a legal protection measure prior to ICU admission and 3-month patient mortality. However, these results must be interpreted with caution due to a potential lack of statistical power. Additionally, legally protected patients were observed to receive renal replacement therapy less frequently, whereas non-invasive ventilation was utilized more frequently. Within this context, further research is required to evaluate the impact of legal protection status on the formal collegial deliberations that lead to decisions regarding the limitation of life-sustaining treatments.
- Open Access
Use of ultrasound for early detection of ICU patients at risk of acquiring swallowing disorders: EIDAR, a prospective diagnostic study protocol
Introduction: Postextubation swallowing disorders (SD) are common in the intensive care unit (ICU) and are associated with severe complications, including aspiration pneumonia, a three-fold increase in reintubation risk and higher mortality. While fibreoptic endoscopic evaluation of swallowing (FEES) and videofluoroscopy are gold standards for diagnosis, they are often impractical or impossible to perform on intubated patients. The use of ultrasound offers a non-invasive, bedside alternative to evaluate the musculoskeletal structures involved in swallowing. The Echographie Identifier les troubles de Déglutition Acquis en Réanimation (EIDAR) study aims to evaluate the diagnostic performance of pre-extubation ultrasound in identifying patients at risk of SD following mechanical ventilation. Methods and analysis: This prospective, monocentric diagnostic study conducted at the Dijon University Hospital ICU will include 100 adult patients ventilated for ≥48 hours. The primary outcome is the presence of SD, defined as a Penetration-Aspiration Scale score >2 during a FEES procedure performed 3 to 24 hours postextubation and independently assessed by an otolaryngologist blinded to index test results. Pre-extubation cervical ultrasound (Index Test) will be performed within 3 hours prior to extubation and measure hyoid bone ascension (primary variable of interest), geniohyoid muscle surface area and digastric muscle cross-sectional area. The diagnostic performance of cervical ultrasonographic parameters will be assessed using their discriminative capacity via a receiver operating characteristic curve. The feasibility of the ultrasound procedure in a critical care setting will also be assessed. Ethics and dissemination: The study received a favourable opinion from the independent ethics committee CPP Ouest III and is registered with the French health authority ANSM (national agency on safety in medicine and health products). It is conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines. Participants or their proxies provide free and informed oral consent. Results will be submitted for publication in peer-reviewed medical journals and presented at international conferences. Trial registration numbers: RCB 2023-A00461-44 and NCT05922085
Open AccessUse of ultrasound for early detection of ICU patients at risk of acquiring swallowing disorders: EIDAR, a prospective diagnostic study protocol
Introduction: Postextubation swallowing disorders (SD) are common in the intensive care unit (ICU) and are associated with severe complications, including aspiration pneumonia, a three-fold increase in reintubation risk and higher mortality. While fibreoptic endoscopic evaluation of swallowing (FEES) and videofluoroscopy are gold standards for diagnosis, they are often impractical or impossible to perform on intubated patients. The use of ultrasound offers a non-invasive, bedside alternative to evaluate the musculoskeletal structures involved in swallowing. The Echographie Identifier les troubles de Déglutition Acquis en Réanimation (EIDAR) study aims to evaluate the diagnostic performance of pre-extubation ultrasound in identifying patients at risk of SD following mechanical ventilation. Methods and analysis: This prospective, monocentric diagnostic study conducted at the Dijon University Hospital ICU will include 100 adult patients ventilated for ≥48 hours. The primary outcome is the presence of SD, defined as a Penetration-Aspiration Scale score >2 during a FEES procedure performed 3 to 24 hours postextubation and independently assessed by an otolaryngologist blinded to index test results. Pre-extubation cervical ultrasound (Index Test) will be performed within 3 hours prior to extubation and measure hyoid bone ascension (primary variable of interest), geniohyoid muscle surface area and digastric muscle cross-sectional area. The diagnostic performance of cervical ultrasonographic parameters will be assessed using their discriminative capacity via a receiver operating characteristic curve. The feasibility of the ultrasound procedure in a critical care setting will also be assessed. Ethics and dissemination: The study received a favourable opinion from the independent ethics committee CPP Ouest III and is registered with the French health authority ANSM (national agency on safety in medicine and health products). It is conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines. Participants or their proxies provide free and informed oral consent. Results will be submitted for publication in peer-reviewed medical journals and presented at international conferences. Trial registration numbers: RCB 2023-A00461-44 and NCT05922085
- 9 June 2026
- Published by Societe de Reanimation de Langue Francaise in Médecine Intensive Réanimation
- Vol. 35 (Spécial Co)
Évolution du métier de réanimateur : impact sur la QVcT
L’évolution du métier de réanimateur doit prendre en compte le bien-être physique et psychologique ainsi que les besoins sociaux des patients et de leurs proches grâce à une humanisation du soin : « le care », tout en considérant les besoins de celles et ceux qui soignent. Cette évolution doit permettre une transition entre le fait de « faire de la réanimation » aux aspects techniques indispensables mais potentiellement « deshumanisants », et le fait de « devenir réanimateur », état d’esprit qui nécessite formation, compagnonnage (acquisition d’un savoir expérientiel) et prise en compte d’une notion de plus en plus prégnante qui est celle de « service rendu » au patient. Ainsi, évoluer de la réanimation proprement dite à « la non-réanimation », à la « dé-réanimation » et au « suivi post-réanimation » constitue la base de la réflexion autour du métier de réanimateur. Cette démarche contribuera à prévenir, grâce aux réflexions partagées et multidisciplinaires, des soins jugés inutiles, une qualité empêchée et une perte de sens au travail, source de souffrance psychique et de perte d’attractivité et de diminution de la fidélisation aux métiers des soins critiques.
- 9 June 2026
- Published by Societe de Reanimation de Langue Francaise in Médecine Intensive Réanimation
- Vol. 35 (Spécial Co)
Évolution du métier de réanimateur : impact sur la QVcT
L’évolution du métier de réanimateur doit prendre en compte le bien-être physique et psychologique ainsi que les besoins sociaux des patients et de leurs proches grâce à une humanisation du soin : « le care », tout en considérant les besoins de celles et ceux qui soignent. Cette évolution doit permettre une transition entre le fait de « faire de la réanimation » aux aspects techniques indispensables mais potentiellement « deshumanisants », et le fait de « devenir réanimateur », état d’esprit qui nécessite formation, compagnonnage (acquisition d’un savoir expérientiel) et prise en compte d’une notion de plus en plus prégnante qui est celle de « service rendu » au patient. Ainsi, évoluer de la réanimation proprement dite à « la non-réanimation », à la « dé-réanimation » et au « suivi post-réanimation » constitue la base de la réflexion autour du métier de réanimateur. Cette démarche contribuera à prévenir, grâce aux réflexions partagées et multidisciplinaires, des soins jugés inutiles, une qualité empêchée et une perte de sens au travail, source de souffrance psychique et de perte d’attractivité et de diminution de la fidélisation aux métiers des soins critiques.
- Open Access
Acceptability and feasibility of a community–hospital parenting support and prevention programme for families of infants at high neurodevelopmental risk following neonatal encephalopathy: protocol of the PRePaR (PRevention and support for Parenthood in early Rehabilitation) mixed-methods study
Introduction Neonatal encephalopathy, particularly situations involving neonatal hypoxic–ischaemic encephalopathy (NHIE) and neonatal stroke (NS), covers complex neonatal conditions associated with a risk of neurodevelopmental difficulties. Early prevention programmes have shown benefits for neurodevelopment, but few address both NHIE and NS populations. Following an initial joint development phase with families and professionals, we identified two areas of intervention: (1) Making infant care and referral more streamlined and (2) Increasing parent empowerment. The PRevention and support for Parenthood in an early Rehabilitation programme is a multidisciplinary intervention initiated in the neonatal intensive care unit and continuing at home until the infant reaches a corrected age of 4 months. Its objectives are to: (1) Ensure that the family environment is adapted to the child’s needs, (2) Introduce parents to digital support suggesting information on the care pathway and developmental interventions, (3) Maintain continuity of care and (4) Maximise early detection by sharing videos for analysis of the child’s movements. Method and analysis This longitudinal study uses a mixed-methods approach to assess the acceptability and feasibility of the early parenthood support programme involving parents and healthcare professionals. The qualitative research will be carried out through focus groups (parents and professionals) held at the end of the intervention programme. The corpus of semidirected collective interviews (focus group) will be processed by thematic content analysis. Initial coding and analysis will be conducted by the sociologist with expertise in qualitative methods, and the emerging themes and interpretations will then be discussed, refined and validated through interdisciplinary analysis meetings involving the broader research team. This collective analytical process will allow for deeper engagement with the data and ensure that interpretations are challenged and enriched by multiple professional perspectives. The quantitative research will rely on self-administered questionnaires (parents and professionals), assessment of child neurodevelopment using standardised tools by physiotherapists and assessment of parental skills using standardised observation grids. Ethics and dissemination This study has full approval from an independent ethics committee (CPP Ile de France I). Its findings will be published in peer-reviewed journals and conference presentations. The trial was registered on Clinicaltrials.gov (NCT05457569).
Open AccessAcceptability and feasibility of a community–hospital parenting support and prevention programme for families of infants at high neurodevelopmental risk following neonatal encephalopathy: protocol of the PRePaR (PRevention and support for Parenthood in early Rehabilitation) mixed-methods study
Introduction Neonatal encephalopathy, particularly situations involving neonatal hypoxic–ischaemic encephalopathy (NHIE) and neonatal stroke (NS), covers complex neonatal conditions associated with a risk of neurodevelopmental difficulties. Early prevention programmes have shown benefits for neurodevelopment, but few address both NHIE and NS populations. Following an initial joint development phase with families and professionals, we identified two areas of intervention: (1) Making infant care and referral more streamlined and (2) Increasing parent empowerment. The PRevention and support for Parenthood in an early Rehabilitation programme is a multidisciplinary intervention initiated in the neonatal intensive care unit and continuing at home until the infant reaches a corrected age of 4 months. Its objectives are to: (1) Ensure that the family environment is adapted to the child’s needs, (2) Introduce parents to digital support suggesting information on the care pathway and developmental interventions, (3) Maintain continuity of care and (4) Maximise early detection by sharing videos for analysis of the child’s movements. Method and analysis This longitudinal study uses a mixed-methods approach to assess the acceptability and feasibility of the early parenthood support programme involving parents and healthcare professionals. The qualitative research will be carried out through focus groups (parents and professionals) held at the end of the intervention programme. The corpus of semidirected collective interviews (focus group) will be processed by thematic content analysis. Initial coding and analysis will be conducted by the sociologist with expertise in qualitative methods, and the emerging themes and interpretations will then be discussed, refined and validated through interdisciplinary analysis meetings involving the broader research team. This collective analytical process will allow for deeper engagement with the data and ensure that interpretations are challenged and enriched by multiple professional perspectives. The quantitative research will rely on self-administered questionnaires (parents and professionals), assessment of child neurodevelopment using standardised tools by physiotherapists and assessment of parental skills using standardised observation grids. Ethics and dissemination This study has full approval from an independent ethics committee (CPP Ile de France I). Its findings will be published in peer-reviewed journals and conference presentations. The trial was registered on Clinicaltrials.gov (NCT05457569).
- Open Access
Immediate versus gradual Tocilizu M ab discontinuAtion in G I ant Cell Arteritis: protocol of the multicentre randomised open-label MAGICA trial
Introduction Giant cell arteritis (GCA) is a large-vessel vasculitis occurring in people aged over 50 years. Recent studies have shown that tocilizumab (TCZ), an anti-IL-6 receptor monoclonal antibody, is remarkably effective in treating GCA and allows significant dose sparing of glucocorticoids. However, it makes it difficult to monitor disease activity. Furthermore, treatment is often prolonged over 1 year due to the fear of relapse after stopping TCZ and/or the absence of an optimal discontinuation scheme. Methods and analysis This study aims at comparing two discontinuation regimens in a population of GCA patients who have been treated with TCZ for 12–36 months and have discontinued glucocorticoids for at least 12 weeks. Patients will be randomised with a 1:1 ratio between two arms: immediate discontinuation (cessation) versus gradual discontinuation of TCZ (162 mg subcutaneously every 2 weeks for 12 weeks and then every 4 weeks for 12 additional weeks). Patients will be followed up for 78 weeks. The primary endpoint is relapse-free survival after 26 weeks of follow-up. A total of 120 patients will be randomised (60 in each group) for a period of 3 years. Ethics and dissemination The trial was approved by an independent ethics committee (CPP Sud Ouest et Outre Mer IV) and the French health authority (French National Agency for Medicines and Health Products Safety—ANSM) through the Clinical Trials Information System (CTIS) provided by the European Medicines Agency (EMA). The informed consent complies with the ICH GCP guideline and regulatory requirements. Eligible patients may only be included in the study after providing informed consent. Findings will be published in peer-reviewed journals and conference presentations. Trial registration number NCT06037460.
Open AccessImmediate versus gradual Tocilizu M ab discontinuAtion in G I ant Cell Arteritis: protocol of the multicentre randomised open-label MAGICA trial
Introduction Giant cell arteritis (GCA) is a large-vessel vasculitis occurring in people aged over 50 years. Recent studies have shown that tocilizumab (TCZ), an anti-IL-6 receptor monoclonal antibody, is remarkably effective in treating GCA and allows significant dose sparing of glucocorticoids. However, it makes it difficult to monitor disease activity. Furthermore, treatment is often prolonged over 1 year due to the fear of relapse after stopping TCZ and/or the absence of an optimal discontinuation scheme. Methods and analysis This study aims at comparing two discontinuation regimens in a population of GCA patients who have been treated with TCZ for 12–36 months and have discontinued glucocorticoids for at least 12 weeks. Patients will be randomised with a 1:1 ratio between two arms: immediate discontinuation (cessation) versus gradual discontinuation of TCZ (162 mg subcutaneously every 2 weeks for 12 weeks and then every 4 weeks for 12 additional weeks). Patients will be followed up for 78 weeks. The primary endpoint is relapse-free survival after 26 weeks of follow-up. A total of 120 patients will be randomised (60 in each group) for a period of 3 years. Ethics and dissemination The trial was approved by an independent ethics committee (CPP Sud Ouest et Outre Mer IV) and the French health authority (French National Agency for Medicines and Health Products Safety—ANSM) through the Clinical Trials Information System (CTIS) provided by the European Medicines Agency (EMA). The informed consent complies with the ICH GCP guideline and regulatory requirements. Eligible patients may only be included in the study after providing informed consent. Findings will be published in peer-reviewed journals and conference presentations. Trial registration number NCT06037460.
- Open Access
- 28 February 2025
- Published by Wolters Kluwer Health in Critical Care Medicine
- Vol. 53 (4) , e884-e896
Dexmedetomidine to Reduce Vasopressor Resistance in Refractory Septic Shock: α2 Agonist Dexmedetomidine for REfractory Septic Shock (ADRESS): A Double-Blind Randomized Controlled Pilot Trial
OBJECTIVES: Increasing evidence has suggested the benefits of dexmedetomidine in patients with sepsis. Dexmedetomidine may increase vasopressor sensitivity, which may be of interest in the setting of refractory septic shock. The α2 Agonist Dexmedetomidine for REfractory Septic Shock (ADRESS) pilot study aimed to evaluate the effect of dexmedetomidine on the vasopressor response in patients with refractory septic shock. DESIGN: This study was a multicenter, randomized, placebo-controlled, double-blind pilot trial. SETTING: The study was conducted in 5 ICUs in France. PATIENTS: Inclusion criteria were septic shock (Sepsis-3 definition) and norepinephrine requirement greater than or equal to 0.25 µg/kg/min (0.5 µg/kg/min of norepinephrine tartrate) with persistent circulatory failure (defined by lactate > 2 mmol/L, oliguria, or skin mottling) and invasive mechanical ventilation. INTERVENTIONS: The arterial pressure response to phenylephrine was measured before starting the treatment (0 hr), at 6 hours (primary outcome), and 12 hours. In the treatment arm, dexmedetomidine was given at a fixed dose of 1 µg/kg/hr. MEASUREMENTS AND MAIN RESULTS: Inclusions were stopped early because of higher mortality in the dexmedetomidine arm. Thirty-two patients of the 36 planned were included. Response to phenylephrine at 6 hours was lower in the dexmedetomidine group than in the placebo group (1.26 ± 0.23 vs. 1.45 ± 0.26; p = 0.048), although this difference was also observed at baseline (p = 0.029). There were no significant differences between the groups in terms of cumulative norepinephrine dose, lactatemia, Sequential Organ Failure Assessment score, fluid balance, ventilation-free days, or occurrence of bradycardia. Mortality on day 3 was higher in the dexmedetomidine group than in the placebo group, with a difference that diminished and was no longer significant on 30 and 90 days. CONCLUSIONS: Patients in the dexmedetomidine arm had a significantly lower response to phenylephrine at all study times including baseline, which might have contributed to higher early mortality in the dexmedetomidine arm and preclude to conclude on dexmedetomidine efficacy in refractory septic shock. However, heart rate was not decreased in the dexmedetomidine arm.
- 28 February 2025
- Published by Wolters Kluwer Health in Critical Care Medicine
- Vol. 53 (4) , e884-e896
Open AccessDexmedetomidine to Reduce Vasopressor Resistance in Refractory Septic Shock: α2 Agonist Dexmedetomidine for REfractory Septic Shock (ADRESS): A Double-Blind Randomized Controlled Pilot Trial
OBJECTIVES: Increasing evidence has suggested the benefits of dexmedetomidine in patients with sepsis. Dexmedetomidine may increase vasopressor sensitivity, which may be of interest in the setting of refractory septic shock. The α2 Agonist Dexmedetomidine for REfractory Septic Shock (ADRESS) pilot study aimed to evaluate the effect of dexmedetomidine on the vasopressor response in patients with refractory septic shock. DESIGN: This study was a multicenter, randomized, placebo-controlled, double-blind pilot trial. SETTING: The study was conducted in 5 ICUs in France. PATIENTS: Inclusion criteria were septic shock (Sepsis-3 definition) and norepinephrine requirement greater than or equal to 0.25 µg/kg/min (0.5 µg/kg/min of norepinephrine tartrate) with persistent circulatory failure (defined by lactate > 2 mmol/L, oliguria, or skin mottling) and invasive mechanical ventilation. INTERVENTIONS: The arterial pressure response to phenylephrine was measured before starting the treatment (0 hr), at 6 hours (primary outcome), and 12 hours. In the treatment arm, dexmedetomidine was given at a fixed dose of 1 µg/kg/hr. MEASUREMENTS AND MAIN RESULTS: Inclusions were stopped early because of higher mortality in the dexmedetomidine arm. Thirty-two patients of the 36 planned were included. Response to phenylephrine at 6 hours was lower in the dexmedetomidine group than in the placebo group (1.26 ± 0.23 vs. 1.45 ± 0.26; p = 0.048), although this difference was also observed at baseline (p = 0.029). There were no significant differences between the groups in terms of cumulative norepinephrine dose, lactatemia, Sequential Organ Failure Assessment score, fluid balance, ventilation-free days, or occurrence of bradycardia. Mortality on day 3 was higher in the dexmedetomidine group than in the placebo group, with a difference that diminished and was no longer significant on 30 and 90 days. CONCLUSIONS: Patients in the dexmedetomidine arm had a significantly lower response to phenylephrine at all study times including baseline, which might have contributed to higher early mortality in the dexmedetomidine arm and preclude to conclude on dexmedetomidine efficacy in refractory septic shock. However, heart rate was not decreased in the dexmedetomidine arm.
- Open Access
- 28 February 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (2) , e0316318
Barriers to and facilitators of rehabilitation according to socio-economic status, after acute respiratory distress syndrome due to COVID-19: A qualitative study in the RECOVIDS cohort
Background: The COVID-19 pandemic may have compounded social disparities in access to healthcare, with possible deleterious consequences on the functional prognosis of patients after a stay in the intensive care unit (ICU). In the previous RECOVIDS study, we reported that despite comparable pulmonary sequelae and similar access to rehabilitation, socio-economically “vulnerable” patients had lower quality of life at 6 months after an ICU stay. We aimed to describe the barriers to, and facilitators of participation in rehabilitation, among patients from the RECOVIDS study, regardless of their socio-economic situation. Methods: Qualitative study using semi-structured interviews with adult patients admitted to ICU for PCR-proven SARS-CoV-2 infection, and who had acute respiratory distress syndrome (ARDS) or had received high flow nasal oxygen. In addition, patients had to have been living at home for the month prior to the interview and had to be proficient in French. Eligible patients were randomly selected, aiming to select the same number of socially deprived and non-socially-deprived patients. Interviews were transcribed for thematic analysis. Results: In total, 31 interviews were performed from 10/2021 to 01/2022; 16 with socially deprived, and 15 with non-deprived participants. Average age was 65.2 (±11.6) years. Four themes emerged from the analysis of the interviews, namely: (1) the impact of the patient’s professional and socio-economic situation; (2) the feeling that age and socio-economic situation influence access to rehabilitation; (3) a perception that the healthcare system was saturated, and that inequalities exist in access to rehabilitation resources; (4) perception of previous own health and expectations of post-resuscitation health status. Conclusion: A precarious socio-economic situation has a substantial impact on access to rehabilitation after ICU admission for ARDS caused by COVID-19. It represents a barrier to rehabilitation through the combined action of various social determinants that deserve to be detected early, in order to take appropriate action to ensure that the most socially vulnerable individuals can benefit from access to rehabilitation.
- 28 February 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (2) , e0316318
Open AccessBarriers to and facilitators of rehabilitation according to socio-economic status, after acute respiratory distress syndrome due to COVID-19: A qualitative study in the RECOVIDS cohort
Background: The COVID-19 pandemic may have compounded social disparities in access to healthcare, with possible deleterious consequences on the functional prognosis of patients after a stay in the intensive care unit (ICU). In the previous RECOVIDS study, we reported that despite comparable pulmonary sequelae and similar access to rehabilitation, socio-economically “vulnerable” patients had lower quality of life at 6 months after an ICU stay. We aimed to describe the barriers to, and facilitators of participation in rehabilitation, among patients from the RECOVIDS study, regardless of their socio-economic situation. Methods: Qualitative study using semi-structured interviews with adult patients admitted to ICU for PCR-proven SARS-CoV-2 infection, and who had acute respiratory distress syndrome (ARDS) or had received high flow nasal oxygen. In addition, patients had to have been living at home for the month prior to the interview and had to be proficient in French. Eligible patients were randomly selected, aiming to select the same number of socially deprived and non-socially-deprived patients. Interviews were transcribed for thematic analysis. Results: In total, 31 interviews were performed from 10/2021 to 01/2022; 16 with socially deprived, and 15 with non-deprived participants. Average age was 65.2 (±11.6) years. Four themes emerged from the analysis of the interviews, namely: (1) the impact of the patient’s professional and socio-economic situation; (2) the feeling that age and socio-economic situation influence access to rehabilitation; (3) a perception that the healthcare system was saturated, and that inequalities exist in access to rehabilitation resources; (4) perception of previous own health and expectations of post-resuscitation health status. Conclusion: A precarious socio-economic situation has a substantial impact on access to rehabilitation after ICU admission for ARDS caused by COVID-19. It represents a barrier to rehabilitation through the combined action of various social determinants that deserve to be detected early, in order to take appropriate action to ensure that the most socially vulnerable individuals can benefit from access to rehabilitation.
- Open Access
- 27 September 2023
- Published by Springer Nature in Intensive Care Medicine
- Vol. 49 (11) , 1438-1439
Correction: Influence of socio-economic status on functional recovery after ARDS caused by SARS-CoV-2: the multicentre, observational RECOVIDS study
- 27 September 2023
- Published by Springer Nature in Intensive Care Medicine
- Vol. 49 (11) , 1438-1439
Open AccessCorrection: Influence of socio-economic status on functional recovery after ARDS caused by SARS-CoV-2: the multicentre, observational RECOVIDS study